anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
10 patients with HPV- and p16INK4a-positive cervical, vulvar, vaginal, penile, anal or head and neck cancer will be enrolled. The p16INK4a-peptide (p16INK4a-37-63, 100 mcg) mixed with MONTANIDE ISA-51 VG (0.3 ml) will be administered subcutaneously once weekly for four weeks, followed by a 4-week rest period (1 cycle). This schedule will be repeated for a total of 3 cycles (= 6 months) or until tumor progression or intolerable toxicity is documented. The first application will be done one week before chemotherapy initiation or continuation. Concurrent radiation is allowed and should be documented. If chemotherapy is withhold for toxicity, vaccination treatment can be continued.

Patients will be seen at baseline/screening and at every visit for safety assessment until disease progression or discontinuation of trial therapy for other reasons. Immunological assessments will be made in all patients. The immunological assessment includes the delayed time hypersensitivity response (DTH) against the P16_37-63 peptide. Therefore in week 1, 9, 17 and 25, 30 mcg P16_37-63 peptide solution without MONTANIDE ISA-51 VG will be injected at a separate site from the vaccination site intradermally. Immunological responses are evaluated at baseline and after vaccination in weeks 9, 17 and 25 (ELISPOT) and in weeks 1, 3, 9, 11, 17, 19 and 25 (ELISA) and are compared to the antigen-specific immune response measured before vaccination (week 1). Radiological tumor assessment (CT, MRI) will be performed at baseline and then every 8 weeks (after every cycle). There will be a follow- up visit four weeks after the last vaccination for safety. Further follow-up regarding progression and death can be performed, e.g. via a phone call. Autoimmunity will be assessed every 8 weeks. Safety of the immunization will be analyzed as assessed by the number and severity of adverse events categorized according to CTC criteria
The device clinic of Aspirus Wausau Hospital follows approximately 2800 patients with pacemakers and automatic implantable cardioverter defibrillators (AICD). Approximately 300 of these patients have had an AICD inserted for primary or secondary arrhythmia prevention. From these 300 patients, approximately 20 patients who have an AICD implanted either prophylactically or for an established malignant arrhythmia will be recruited for this short study.

This is a study to investigate the effect of ranolazine on arrhythmias detected by their device to see if it will reduce abnormal beats. It will also study whether ranolazine will impact microvolt t-wave alternans (MVTWA), a measure of the tendency to have a serious arrhythmia. Approximately 10 patients with ischemic cardiomyopathy and 10 patients with a non-ischemic cardiomyopathy will be chosen. All will have an ejection fraction of 40% or less. Prior to institution of ranolazine, a MVTWA study will be performed (Cambridge Heart Inc.®). The AICD will be used to generate the increase in the heart rate needed to induce MVTWA. Each patient will have MVTWA assessed at 80 beats/minute and then again at 110 beats/minute. To eliminate interpretation bias, the auto interpretation feature of the MVTWA device will be used to determine whether the study is positive (MVTWA present) or negative (MVTWA absent) or indeterminate. In the coarse of this study, each patient will undergo a total of 3 MVTWA studies in an identical manner using the AICD to provide the needed changes in heart rate.

After informed consent is obtained the patient will begin a 10-day "ranolazine run in". Each randomized participant will be given a 10-day supply of ranolazine to make certain they tolerate the medication (constipation is by far the most common limiting side effect). Each participant will be started on 500 mg BID and after 3 days increased to 1000 mg BID. Participants able to tolerate at least 500 mg BID will then be considered eligible to participate in the study and randomly assigned to either ranolazine at 1000 mg BID (or 500 mg BID if the 1000 mg dose was not tolerated) or a comparable placebo for the next 4 weeks.

At least 3 days after the run in and prior to randomization, each patient will be brought in for or the baseline MVTWA and the device clinic will purge the AICD of data and reset the data counter. The patient will then immediately begin either placebo or ranolazine according to randomization. After 4 weeks, the MVTWA study will be repeated on either placebo or ranolazine and the arrhythmia data down loaded from the AICD, recorded and the arrhythmia counters and device operation counter again reset. Each patient will then cross over to the other therapy (ranolazine or placebo) for the next 4 weeks and the device interrogated and the MVTWA study repeated in an identical manner.
The Dexmedetomidine group will receive dexmedetomidine infusion at a rate of 0.1ug/kg/h. The intervention will commence immediately after induction and will persist until 8 am on the next day.
Although it has been established that patients with chronic kidney disease and iron deficiency, as indicated by a transferrin saturation of < 20%, are at increased risk of all-cause mortality and cardiovascular events, the optimal management of such patients has not yet been determined. In this post hoc subgroup analysis, we aimed to clarify the effect of ferric citrate hydrate on transferrin saturation in patients with chronic kidney disease and low transferrin saturation (< 20%) undergoing hemodialysis. To accomplish this, we extracted the relevant data on a subset of patients drawn from two previous studies: the ASTRIO study (A Study examining the contribution to Renal anemia treatment with ferric citrate hydrate, Iron-based Oral phosphate binder, UMIN000019176) and a post-marketing surveillance study. The subset of patients used for the present study were those with baseline transferrin saturation < 20%. We found that administration of ferric citrate hydrate increased transferrin saturation and maintained transferrin saturation at approximately 30%. However, because we did not have access to data on all-cause mortality or cardiovascular events, we could not ascertain whether the frequency of these outcomes was reduced in parallel with improvements in transferrin saturation. Further large studies are required.
Patients receive tamoxifen PO QD on days 1-28 of each cycle and pegylated liposomal doxorubicin IV on day 1 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo echocardiography, CT scan or MRI, tumor biopsy, and blood sample collection throughout the study.
Plasmacytoid dendritic cells (pDCs) are key actors of innate immunity that produce high levels of interferon (IFN)-alpha after activation of their Toll-Like Receptors (TLR) by pathogens. A difference between men and women has recently been shown in the level of IFN-alpha produced by pDCs after TLR activation. The production of IFN-alpha in response to TLR7 activation is higher in the presence of estrogens. This could be responsible for gender differences in the level of plasma HIV-1 RNA, that is lower in female as compared to male by about 50%, and for the sex-based differences in the susceptibility to HIV infection. Besides the role of estrogens, X-linked genetic factors could also be involved in the sex-dependent differences in the TLR7-mediated responses of pDCs. TLR7 gene is located on the X chromosome. A single nucleotide polymorphism (SNP) of the TLR7 gene, c.32A\>T, have been associated with accelerated disease progression in male HIV patients, and was found over represented in female HIV as well as HCV patients, suggesting that the T allele is associated with a gender-dependent increase of susceptibility to RNA virus infections. A peripheral blood sample will be collected from HIV-infected women and healthy control to measure TLR-7 SNP frequency by PCR. IFN-alpha production from pDCs after HIV-1 RNA sensing by TLR7 will also be assessed.
This invention is directed to methods for preventing the emergence of multidrug resistance in tumor cells during cancer chemotherapy. In particular, it relates to the use of cytoplasmic calcium antagonists and calmodulin inhibitors, phosphoinositol-dependent phospholipase C inhibitors, and substances that inhibit activation of the transcription factor NF-kappaB to prevent the induction of expression of the multidrug resistance gene (MDR1) encoding P-glycoprotein by chemotherapeutic drugs. MDR1 expression, which results in tumor cell resistance to subsequent treatment with certain chemotherapeutic drugs, is shown herein to be induced in response to treatment with various cytotoxic agents, including such agents that are or are not substrates for P-glycoprotein-mediated efflux from cancer cells. Cytoplasmic calcium antagonists and calmodulin inhibitors, phosphoinositol-dependent phospholipase C inhibitors, and substances that inhibit activation of the transcription factor NF-kappaB are shown herein to suppress this cellular response. The invention also provides methods for identifying cytoplasmic calcium antagonists and calmodulin inhibitors, phosphoinositol-dependent phospholipase C inhibitors, and substances that inhibit activation of the transcription factor NF-kappaB that suppress induction of MDR1 gene expression by cytotoxic drugs. Thus, the invention provides useful methods and reagents for preventing the emergence of multidrug resistance in tumor cells treated with cytotoxic and chemotherapeutic drugs in cancer patients undergoing chemotherapy, when cytoplasmic calcium antagonists and calmodulin inhibitors, phosphoinositol-dependent phospholipase C inhibitors, and substances that inhibit activation of the transcription factor NF-kappaB are administered prior to or simultaneously with cytotoxic drug treatment in such individuals.
A burn and scald medicine coating liquid and a preparation method and a use method thereof relate to a burn and scald medicine and a preparation method and a use method thereof. The preparation method comprises the following steps of a, preparing the second layer of skin of the fresh cherokee rose-hip root: cleaning fresh fructus Rosae Laevigatae root, removing epidermis, and scraping the second layer of skin. b. Preparing a second-layer water boiling solution of fresh cherokee rose root: and (3) putting the second-layer skin of the fresh cherokee rose root and spring water into a boiler, heating and boiling, boiling for about 30 minutes, filtering to obtain a coarse boiling liquid, putting the coarse boiling liquid into the boiler, boiling for about 60 minutes, and filtering to obtain the second-layer skin water boiling liquid of the fresh cherokee rose root. c. Preparing a burn and scald masking liquid; decocting fresh second layer of fructus Rosae Laevigatae root in water, adding Lumbricus powder, Borneolum Syntheticum, oleum Verniciae Fordii, and folium Rosae Laevigatae powder, and mixing to obtain the final product. The traditional Chinese medicine composition has the advantages of simple formula, easy preparation, convenient medication, quick pain relief, quick wound surface drying, quick scabbing, short treatment course, wide application range, low treatment cost, no need of skin grafting and easy popularization.
During Combination Therapy, placebo will be given with a protocol-approved platinum doublet (either carboplatin/paclitaxel, carboplatin/pemetrexed, or cisplatin/pemetrexed) for at least 4, but not more than 6 cycles. Participants who experience clinical benefit from the Combination Therapy will enter the Monotherapy Phase and receive placebo as monotherapy until disease progression.
PURPOSE:The titled drug that contains an aminobenzoic acid derivative or its salt as an active ingredient, thus permitting long-term administration, because of its low toxicity. CONSTITUTION:The objective antithrombotic agent is obtained by using 0.01- 100wt% of at least one of the compounds of the formula (R is glycoside) or their salts such as p-aminobenzoic acid-N-L-arabinoside and mixing it with diluents such as extender, binder, humectant, disintegrator and so on. It is effective to not only thrombosis in arteries and veins but also thrombopathy, improvement in thrmoboses accompanied by artificial membranes, renal transplantation, artificial dialysis. Further it is effective to nephrectopathy such as glomerulonephritis. The drug is orally administered 0.1-1,000mg/kg/day, parenterally 0.01-200mg/day. Further, since the compound of the formula has no antibacterial activity, there is no anxiety of disturbing intestinal flora and it exerts no influence on mutagenecity, cellular and humoral immunities, thus it is a very safe drug.
ABSTRACT      The present invention involves the synthesis and use of new platinum compounds.  These new platinum compounds are easy to encapsulate in liposomes at high efficiencies.          They are further characterized as platinum (II) four coordinate complex having the formula:                     wherein R1 and R2 are carboxylato monoanions bearing a hydrophobic radical function or a single carboxylato dianion bearing a hydrophobic radical function and R3 is a vicinal diaminoalkane or vicinal diaminocycloalkane.  The complex is substantially soluble in methanol or chloroform and substantially insoluble in water.  Said complex may be incorporated into phospholipid liposomes.  Such platinum complexes encapsulated in phospholipid liposomes are useful for chemotherapy of platinum complex-sensitive tumors.
An anti-acne and skin-care product comprises the following raw materials: phellodendron, sulphur, scutellaria, rhubarb, and dandelion. The above herbs are carefully selected, processed, and pulverized into fine powder; the powder is sieved respectively by sieves of 80-200 meshes, uniformly mixed, filled and sealed into a special clean bottle; and the powder can be mixed with water to become a paste or can be prepared into powder, cream, frost, etc. After a face is washed by cold water and is dried, the product (not less than 5g) is mixed with water to become a paste and is applied to the affected part. The face is washed clean on the next day. The product is used once a day, four hours before sleep, and continues for a week. The invention adopts an old traditional Chinese medicine formula, selects pure natural Chinese herbal medicine (suitable for oral administration), has the advantages of clearing heat and detoxification, detumescence and dispelling carbuncle, eliminating dampness and purging internal fire, deinsectization, softening cuticle, and perishing skin parasites, has inhibition effect on bacteria, virus, and fungi, and is applicable to surgical diseases such as skin and the like. The product has quick effect, short treatment course, high cure rate, difficult recurrence, convenient and safe application, and moderate price.
Formulations and methods have been developed for delivering antigens to individuals in a manner that substantially reduces contact between the antigen and IgE receptors displayed on the surfaces of cells involved in mediating allergic responses. By reducing direct and indirect association of antigens with antigen-specific IgE antibodies, the risk of an allergic reaction, possibly anaphylatic shock, is reduced or eliminated. In the preferred embodiments, the compositions include one or more antigens in a delivery material such as a polymer, in the form of particles or a gel, or lipid vesicles or liposomes, any of which can be stabilized or targeted to enhance delivery. Preferably, the antigen is surrounded by the encapsulation materiel. One result of encapsulating antigen is the reduction in association with antigen-specific IgE antibodies. In a preferred embodiment, the formulation is designed to deliver antigens to individuals in a manner designed to promote a Th1-type mediated immune response and/or in a manner designed to suppress a Th2 response. In still another embodiment, the formulation effects preferential release of the antigen within APCs.
It has been well-investigating that individual phthalates (PAEs) or polycyclic aromatic hydrocarbons (PAHs) affect public health. However, there is still a gap that the mixture of PAEs and PAHs impacts birth outcomes. Through innovative methods for mixtures in epidemiology, we used a metabolome Exposome-Wide Association Study (mExWAS) to evaluate and explain the association between exposure to PAEs and PAHs mixtures and birth outcomes. Exposure to a higher level of PAEs and PAHs mixture was associated with lower birth weight (maximum cumulative effect: 143.5 g) rather than gestational age. Mono(2-ethlyhexyl) phthalate (MEHP) (posterior inclusion probability, PIP = 0.51), 9-hydroxyphenanthrene (9-OHPHE) (PIP = 0.53), and 1-hydroxypyrene (1-OHPYR) (PIP = 0.28) were identified as the most important compounds in the mixture. In mExWAS, we successfully annotated four overlapping metabolites associated with both MEHP/9-OHPHE/1-OHPYR and birth weight, including arginine, stearamide, Arg-Gln, and valine. Moreover, several lipid-related metabolism pathways, including fatty acid biosynthesis and degradation, alpha-linolenic acid, and linoleic acid metabolism, were disturbed. In summary, these findings may provide new insights into the underlying mechanisms by which PAE and PAHs affect fetal growth.
Acute kidney injury (AKI) is a life-threatening disease primarily caused by renal ischemia-reperfusion (I/R) injury, which can result in renal failure. Currently, growth factor therapy is considered a promising and effective approach for AKI treatment. Basic fibroblast growth factor (bFGF), an angiogenic factor with potent activity, efficiently stimulates angiogenesis and facilitates regeneration of renal tissue. However, the unrestricted diffusion of bFGF restricts its clinical application in AKI treatment. Therefore, developing a novel sustained released system for bFGF could enhance its potential in treating AKI. In this study, we genetically engineered a multifunctional recombinant protein by fusing bFGF with a specific peptide (EBP). EBP-bFGF effectively binds to the extracellular matrix in the injured kidney, enabling slow release of bFGF in AKI. Furthermore, following orthotopic injection into I/R rats' ischemic kidneys, EBP-bFGF exhibited stable retention within the tissue. Additionally, EBP-bFGF suppressed apoptosis of renal cells, reduced renal fibrosis, and facilitated recovery of renal function. These findings suggest that EBP-bFGF delivery system represents a promising strategy for treating AKI.
Autism spectrum disorder (ASD) is characterized by persistent social communication deficits and restricted behaviors. Global prevalence is 1-2%, with 1% in Taiwan. Social interaction obstacles and repetitive behaviors impact ASD individuals in various contexts, emphasizing the need for effective interventions. Current treatments focus on behavioral approaches, particularly Naturalistic Developmental Behavioral Interventions (NDBIs). NDBIs improve social engagement, cognitive development, and language skills. Parent-mediated intervention (PMI) enhances treatment effectiveness and reduces parenting stress. However, many NDBIs are conducted in one-on-one settings, limiting feasibility, especially in schools. Group-based interventions are beneficial and more feasible in the communities, but limited research exists. In Taiwan, early interventions, covered by National Health Insurance, lack intensity and parent involvement. The study aims to establish an intensive, parent-involved, group-based NDBIs program. The randomized controlled trial will assess its effectiveness in improving autistic symptoms, social and play skills, group behaviors, general adaptation, and reducing parenting stress.
PURPOSE:To obtain a new compound having a platelet coagulation inhibitory effect owing to a GPIIa/IIIa antagonistic effect and useful as an anti- thrombogenic agent, etc. CONSTITUTION:A compound of formula I [R<1> is aminopiperidyl or aminodiphenyl; R<2> is H or an ester residue; A1 is a single bond or a lower alkylene; A2 is a lower alkylene; (n) is 0 or 1], e.g. ethyl-(R)-4-[4-(4-amidinoben zyloxy)benzyl]-2-oxoxazol idine-3-acetate. The compound of formula I is synthesized by reacting a compound of formula If with an alcohol in the presence of hydrochloric acid gas at -40 to 0 deg.C to obtain an imidate and subsequently reacting an amine or an amine salt (e.g. ammonia) therewith. This compound is ueful as a medicine for improving ischemic heart diseases (unstable angina pectoris, acute myocardial infarction, etc.), an adjuvant for operation in cardiosurgery or vascular surgery, a medicine for improving cerebrovascular diseases or peripheral arterial diseases and can be orally administrated.
BACKGROUND: Acupuncture as a traditional Chinese medicine therapy relies on unique theories to alleviate fatigue. The aim of this study is to evaluate the effect of acupuncture on exercise-induced fatigue utilizing transcranial magnetic stimulation (TMS).
METHODS: A total of 20 participants with regular exercise habits were recruited for this study. All participants were randomly assigned to receive either acupuncture or sham acupuncture intervention for exercise-induced fatigue. TMS and a heart rate monitor were used to measure the amplitude and latency of motor evoked potential (MEP) as well as heart rate every 5 min over a 30-min period. The blood lactic acid (BLA) levels were measured using Lactate Scout+ at baseline, 0 min, and 30 min after fatigue. Two-way repeated measures analysis of variance was utilized to compare the differences between the effects of acupuncture method and time. Bonferroni post hoc tests were conducted to compare specific differences. Statistical significance was set at p < .05.
RESULTS: Interaction effect was observed between acupuncture method and time effect in terms of amplitude (F(1, 38) = 5.40, p < .001, η2 = 0.12) and latency (F(1, 38) = 3.78, p = .008, η2 = .09) of MEP. The application of acupuncture can promote the recovery of heart rate especially at 30 min (p < .05), but which seem insufficient to generate significant difference in BLA (F(1, 38) = 0.067, p = .797, η2 = 0.002).
CONCLUSIONS: Acupuncture can promote the increase of MEP amplitude, shorten MEP latency, and restore heart rate. Preliminary findings provide novel insights for individuals with exercise habits to alleviate fatigue and enhance sports performance.
PURPOSE:To enhance the percutaneous absorptivity of a drug over a long period of time and to prevent the degradation in tacky adhesiveness over a long period of time by providing a tacky adhesive layer contg. the drug and a drug dissolution assistant on a drug impermeable base. CONSTITUTION:This percutaneous absorbing pharmaceutical is constituted by providing the tacky adhesive layer contg. the drug and the drug dissolution assistant on the drug impermeable base. The tacky adhesive is constituted of a copolymer mainly consisting of N-vinyl-2-pyrrolidone(VP) and a (meth) acrylate and has pressure-sensitive adhesiveness. The drug dissolution assistant is a polyvinyl pyrrolidone(PVP) and the drug is a hydrophilic drug of >=6wt.% saturation solubility to the polyvinyl pyrrolidone. The solubility of the hydrophilic drug is enhanced without degrading the pressure-sensitive adhesiveness if the specified amt. of VP is copolymerized with the (meth)acrylate and the PVP is mixed. The compatibility with the PVP is insufficient if the ratio of VP in the copolymer is excessively low. The pressure-sensitive adhesiveness is impaired if this ratio is excessively high. VP is, therefore, incorporated preferably at 10 to 35wt.% copolymn. ratio in the copolymer.